

Lao People's Democratic Republic

Tuberculosis profile

Population 2018

7.1 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	11 (7.4–16)	162 (105–231)
HIV-positive TB incidence	0.72 (0.46–1)	10 (6.5–15)
MDR/RR-TB incidence ^{oo}	0.16 (0.065–0.28)	2.2 (0.92–4)
HIV-negative TB mortality	2.1 (1.3–3.2)	30 (18–46)
HIV-positive TB mortality	0.27 (0.17–0.39)	3.8 (2.4–5.5)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	1.2% (0.5–2)
Previously treated cases	4.1% (0–9.6)

TB case notifications, 2018

Total new and relapse	6 548
- % tested with rapid diagnostics at time of diagnosis	63%
- % with known HIV status	81%
- % pulmonary	92%
- % bacteriologically confirmed ^{ooo}	65%
- % children aged 0-14 years	2%
- % women	36%
- % men	62%
Total cases notified	6 729

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	57% (40–89)
TB patients facing catastrophic total costs, 2019	63% (59–66)
TB case fatality ratio (estimated mortality/estimated incidence), 2018	22% (11–35)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	337	6%
- on antiretroviral therapy	260	77%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	51%
- Previously treated cases	98%
Laboratory-confirmed cases*	MDR/RR-TB: 52, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 44, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	24

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	89%	5 730
Previously treated cases, excluding relapse, registered in 2017	84%	222
HIV-positive TB cases registered in 2017	69%	325
MDR/RR-TB cases started on second-line treatment in 2016	82%	33
XDR-TB cases started on second-line treatment in 2016		0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	18% (16–19)

TB financing, 2019

National TB budget (US\$ millions)	3.7
Funding source: 20% domestic, 80% international, 0% unfunded	

^o Ranges represent uncertainty intervals


^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history


** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females ■ Males Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically